Icon Writers
Cyclowest Pty Limited (Cyclowest), a leading provider of GMP radiopharmaceutical manufacturing and expertise for clinical trials and research, has joined forces with Icon Cancer Centre (Icon) to accelerate innovation in theranostics and molecular imaging across Australia.
Cyclowest Pty Limited (Cyclowest), a leading provider of GMP radiopharmaceutical manufacturing and expertise for clinical trials and research, has joined forces with Icon Cancer Centre (Icon) to accelerate innovation in theranostics and molecular imaging across Australia.
What this partnership mean for patients
- Accelerated innovation: By combining Cyclowest’s radiochemistry expertise with Icon’s experienced clinical network, the partnership will fast-track the translation of cutting-edge research into real-world patient care.
- Expanded access: Patients in Western Australia and beyond will benefit from greater access to the latest diagnostic and therapeutic radiopharmaceuticals, delivered through early phase clinical trials at Icon Cancer Centre – Theranostics and Molecular Imaging.
- Collaborative excellence: Both organisations are committed to the highest standards of safety, compliance, and professional care, ensuring that every project meets rigorous clinical and regulatory requirements.
- Driving research: The partnership creates a platform for pharma-sponsored trials, supporting the development of new theranostics agents and therapies that have the potential to transform cancer treatment.
Personalised medicine milestone
Group Chief Medical Officer, Dr Ian Irving shared his enthusiasm for the partnership.
“The collaboration between Cyclowest and Icon represents a major milestone for theranostics in Australia,” said Dr Irving.
“By combining our strengths, we’re able to accelerate research, improve clinical outcomes, and offer patients access to the latest advancements in personalised medicine.
“We look forward to working closely with Cyclowest to set new standards in patient care and innovation.”
Through this collaboration, Cyclowest’s experts will support the development of new diagnostic and therapeutic radiopharmaceuticals for pharma-sponsored early phase theranostics cancer trials in Western Australia.
Looking ahead
With a shared vision for advancing cancer care, Icon and Cyclowest are set to deliver meaningful change for patients, clinicians, and the broader healthcare community.
The partnership follows Icon’s continued investment in the latest treatments, techniques and personalised medicines